News

Video

Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need

Author(s):

Xiuning Le, MD, PhD

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.

Related Videos
Nicolas Girard, MD
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Shirish M. Gadgeel, MD
Jacob Sands, MD
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Charu Aggarwal, MD, MPH, FASCO
Andrea Wolf, MD, MPH
Nagashree Seetharamu, MD, MBBS
Shirish M. Gadgeel, MD
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Related Content
FDA
October 3rd 2024

FDA Approves Perioperative Nivolumab for Resectable NSCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.
September 28th 2024

The OncFive: Top Oncology Articles for the Week 9/22

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Danny Nguyen, MD
September 23rd 2024

BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC

Jason Zhu, MD, MBA, executive director and chief executive officer of Henlius Biotech
September 23rd 2024

First-Line Serplulimab Receives Positive CHMP Opinion for ES-SCLC